4 results match your criteria: "Oregon Health and Science University Portland OR 97239 USA cohenmic@ohsu.edu.[Affiliation]"
Article Synopsis
- Aficamten is a new drug that helps reduce heart issues in patients with obstructive hypertrophic cardiomyopathy by targeting heart muscle contractility and maintaining safe blood flow levels.
- * In a clinical trial involving 282 patients, those receiving aficamten were able to maintain effective heart function with minimal side effects, including a stable reduction in heart muscle contraction without significant adverse events.
- * The findings suggest that using a tailored dosing strategy for aficamten is effective and safe, improving cardiovascular health without worsening conditions like heart failure.
Structure-guided design and characterization of a clickable, covalent PARP16 inhibitor.
Chem Sci
November 2022
Department of Chemical Physiology and Biochemistry, Oregon Health & Science University Portland OR 97239 USA
PARP16-the sole ER-resident PARP family member-is gaining attention as a potential therapeutic target for cancer treatment. Nevertheless, the precise function of the catalytic activity of PARP16 is poorly understood. This is primarily due to the lack of inhibitors that are selective for PARP16 over other PARP family members.
View Article and Find Full Text PDFRational design of selective inhibitors of PARP4.
RSC Med Chem
November 2021
Department of Chemical Physiology and Biochemistry, Oregon Health and Science University Portland OR 97239 USA
PARPs (PARP1-16 in humans) are a large family of ADP-ribosyltransferases (ARTs) that have diverse roles in cellular physiology and pathophysiology. Most PARP family members mediate mono-ADP-ribosylation (MARylation) of targets. The function of PARP-mediated MARylation in cells is poorly characterized, due in large part to the paucity of selective small molecule inhibitors of the catalytic activity of individual PARP enzymes.
View Article and Find Full Text PDFArticle Synopsis
- * A study conducted from April 3 to June 19, 2020, found that among 3,248 frontline HCP, 6% tested positive for SARS-CoV-2 antibodies, with significant variability in infection rates across hospitals.
- * Many infected HCP were asymptomatic or did not recognize their infection, highlighting the need for enhanced screening and the consistent use of personal protective equipment (PPE) to minimize virus transmission in healthcare settings.